CARL vs SYK
CARL: Carlsmed is a medical technology company revolutionizing spinal surgery with AI-enabled, patient-specific implants that improve outcomes and surgical precision. SYK: A diversified global MedTech leader providing surgical instruments, robotics, and advanced clinical technologies to enhance patient recovery and healthcare outcomes.
Side-by-side fundamentals
| Metric | CARL | SYK | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $14.31 | $297.60 | |
| Market cap | $391M | $114.2B | |
| P/E as of 2026-10-21 | n/a | 30.84 | |
| PEG as of 2026-10-21, 3-year EPS CAGR to FY2025 | n/a | 2.85 | |
| Net margin FY2025, SEC XBRL | n/a | +12.9% | |
| Gross margin FY2025, SEC XBRL | n/a | +64.0% | |
| Operating margin FY2025, SEC XBRL | n/a | +19.5% | |
| ROE FY2025, SEC XBRL | -30.0% | +14.5% | SYK higher |
| ROA FY2025, SEC XBRL | -22.8% | +6.8% | SYK higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.18 | 0.60 | CARL lower |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +11.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +10.8% | |
| Dividend yield as of 2026-09-02 | n/a | +1.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 8 | SYK higher |
| Beta as of 2026-09-03 | 1.26 | 0.55 | |
| 1-year return as of 2026-10-21 close | +1.5% | -21.6% | CARL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.